Review Special Issues

Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease

  • Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.

    Citation: Anmol Kumar, Ajay Kumar Gupta, Prashant Kumar Singh. Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease[J]. AIMS Neuroscience, 2024, 11(3): 312-340. doi: 10.3934/Neuroscience.2024020

    Related Papers:

    [1] Evangelia G. Chrysikou, John S. Gero . Using neuroscience techniques to understand and improve design cognition. AIMS Neuroscience, 2020, 7(3): 319-326. doi: 10.3934/Neuroscience.2020018
    [2] Elena Rusconi, Jemma Sedgmond, Samuela Bolgan, Christopher D. Chambers . Brain Matters…in Social Sciences. AIMS Neuroscience, 2016, 3(3): 253-263. doi: 10.3934/Neuroscience.2016.3.253
    [3] Carmelo M Vicario, Chiara Lucifora . Neuroethics: what the study of brain disorders can tell about moral behavior. AIMS Neuroscience, 2021, 8(4): 543-547. doi: 10.3934/Neuroscience.2021029
    [4] Carolyn E. Jones, Miranda M. Lim . Phasic Sleep Events Shape Cognitive Function after Traumatic Brain Injury: Implications for the Study of Sleep in Neurodevelopmental Disorders. AIMS Neuroscience, 2016, 3(2): 232-236. doi: 10.3934/Neuroscience.2016.2.232
    [5] John Bickle . The first two decades of CREB-memory research: data for philosophy of neuroscience. AIMS Neuroscience, 2021, 8(3): 322-339. doi: 10.3934/Neuroscience.2021017
    [6] UCHEWA O. Obinna, EMECHETA S. Shallom, EGWU A. Ogugua, EDE C. Joy, IBEGBU O. Augustine . Neuromodulatory roles of PIPER GUINEENSE and honey against Lead-Induced neurotoxicity in social interactive behaviors and motor activities in rat models. AIMS Neuroscience, 2022, 9(4): 460-478. doi: 10.3934/Neuroscience.2022026
    [7] Chiyoko Kobayashi Frank . Reviving pragmatic theory of theory of mind. AIMS Neuroscience, 2018, 5(2): 116-131. doi: 10.3934/Neuroscience.2018.2.116
    [8] Lídia Puigvert Mallart, Ramón Flecha García, Sandra Racionero-Plaza, Teresa Sordé-Martí . Socioneuroscience and its contributions to conscious versus unconscious volition and control. The case of gender violence prevention. AIMS Neuroscience, 2019, 6(3): 204-218. doi: 10.3934/Neuroscience.2019.3.204
    [9] Robert A. Moss . Psychotherapy in pain management: New viewpoints and treatment targets based on a brain theory. AIMS Neuroscience, 2020, 7(3): 194-207. doi: 10.3934/Neuroscience.2020013
    [10] Robert A. Moss . A Theory on the Singular Function of the Hippocampus: Facilitating the Binding of New Circuits of Cortical Columns. AIMS Neuroscience, 2016, 3(3): 264-305. doi: 10.3934/Neuroscience.2016.3.264
  • Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.



    Magnetohydrodynamics(MHD) is a subject that studies the motion of conductive fluids in magnetic fields. It is mainly used in astrophysics, controlled thermonuclear reactions and industry. The system of MHD equations is a coupled equation system of Navier-Stokes equations of fluid mechanics and Maxwell's equations of electrodynamics (see[1,2]). In this paper, we consider the unsteady incompressible MHD equations as follows:

    {ut+(u)uνu+μB×curlB+p=f,xΩ,u=0,xΩ,Bt+Rm1curlcurlBcurl(u×B)=g,xΩ,B=0,xΩ, (1.1)

    where u is velocity, ν kinematic viscosity, μ magnetic permeability, p hydrodynamic pressure, B magnetic field, f body force, and g applied current. The coefficients are the magnetic Reynolds number Rm. As in [3], we assume that Ω is a convex domain in Rd, d=2,3 and t[0,T]. Here, ut=ut, Bt=Bt. The term u×B explains the effect of hydrodynamic flow on current. The magnetic Reynolds number Rm is moderate or low (from 102 to 1) (see[4]). For the purposes of simplicity, we choose Rm=1 in our numerical analysis.

    System (1.1) is considered in conjunction with the following initial boundary conditions

    u(x,0)=u0(x),B(x,0)=B0(x),xΩ,u=0,Bn=0,n×curlB=0,xΩ,t>0,

    where n denotes the outer unit normal of Ω.

    Over that last few decades, there has been a lot of works devoted on the numerical solution of MHD flows. In [5], some mathematical equations related to the MHD equations have been studied. In [6], a weighted regularization approach was applied to incompressible MHD problems. Reference [7,8] decoupled the linear MHD problem involving conducting and insulating regions. A mixed finite element method for stationary incompressible MHD equations was given in [9]. In order to avoid in-sup condition, Gerbeau [10] presented a stabilized finite element method and Salah et al. [11] proposed a Galerkin least-square method. In [12], a two-level finite element method with a stabilizing sub-grid for the incompressible MHD equations has been shown.

    Recently, a convergence analysis of three finite element iterative methods for 2D/3D stationary incompressible MHD equations has been given by Dong and He (see[13]). In order to continue the in-depth explore of three-dimensional incompressible MHD system, an unconditional convergence of the Euler semi-implicit scheme for the three-dimensional incompressible MHD equations was studied by He [14]. In [15], a two-level Newton iteration method for 2D/3D steady incompressible MHD equation was proposed by Dong and He. In addition, Yuksel and Ingram have discussed the full discretization of Grank-Nicolson scheme at small magnetic Reynolds numbers (see[16]). The defect correction finite element method for the MHD equations was shown by Si et. al. [17,18,19]. In [20], a decoupling penalty finite element method for the stationary incompressible MHD equation was presented. To further study this method, we can refer to [21,22,23].

    In this paper, a modified characteristics projection finite element method for the unsteady incompressible magnetohydrodynamics(MHD) equations will be given. In this method, modified characteristics finite element method and the projection method will be combined for solving the incompressible MHD equations. Both the stability and the optimal error estimates both in L2 and H1 norms for the modified characteristics projection finite element method will be derived. In order to demonstrate the effectiveness of our method, we will present some numerical results at the end of the manuscript. The contents of this paper are divided into sections as follows. To obtain the unconditional stability and optimal error estimates, in section 2, we introduce some notations and present a modified characteristics projection algorithm for the MHD equations. Then, in section 3, we give stability and error analysis and show that this method has optimal convergence order by mathematical induction. In order to demonstrate the effectiveness of our method, some numerical results are presented in the last section.

    In this section, we introduce some notations. We employ the standard Sobolev spaces Hk(Ω)=Wk,2, for nonnegative k with norm vk=(k|β|=0Dβv20)1/2. For vector-value function, we use the Sobolev spaces Hk(Ω)=(Hk(Ω))d with norm vk=(di=1vi2k)1/2(see [24,25]). For simplicity, we set:

    X=H10(Ω)2,X0={vX:v=0},M=L20(Ω)={qL2(Ω)d:Ωq(x)dx=0},H={vL2(Ω)d:v=0},W={ψ(H1(Ω))d:ψn|Ω=0},W0={ψW:ψ=0},

    which are equipped with the norms

    vX=v0,qM=q0,ψW=ψ1.

    In this paper, we will use the following equality

    curl(ψ×B)=BψψB,ψ,BW0.

    Then, we recall the following Poincaré-Friedrichs inequality in W: there holds

    c0Ccurlc0,cW,

    with a constant C>0 solely depending on the domain Ω; (see[26]). Here, we define the following trilinear form a1(,,) as follows, for all uV, w,vX,

    a1(u,v,w)=(uw+12(u)w,v)=12(uw,v)12(uv,w)

    and the properties of the trilinear form a1(,,) [27] are helpful in our analysis

    a1(u,v,w)=a1(u,w,v),  uX0,v,wX,|a1(u,v,w)|N2u0(v0wL+vL6wL3),  uL2(Ω)2, vX,wL(Ω)2X,|a1(u,v,w)|N2(uLv0+uL3vL6)w0,  uL(Ω)2X, vX,wL2(Ω)2,v0γ0v0,vL6Cv0,wL4C0w0,  wX,

    where N>0 is a constant, γ0 (only dependent on Ω) is a positive constant, and C0 (only dependent on Ω) is an embedding constant of H1(Ω)L4(Ω) ( denotes the continuous embedding).

    Furthermore, we define the Stokes operator A:D(A)˜H such that A=P, where D(A)=H2(Ω)dX0 and P is an L2-projection from L2(Ω)d to ˜H={vL2(Ω)d;v=0,vn|Ω=0}.

    Next, we recall a discrete version of Gronwall's inequality established in [14].

    Lemma 2.1 Let C0,an,bn and dn, for integers n0, be the non-negative numbers such that

    am+τmn=1bnτm1n=1dnan+C0   m1. (2.1)

    Then

    am+τmn=1bnC0exp(τm1n=1dn)   m1. (2.2)

    Throughout this paper, we make the following assumptions on the prescribed date for the problem (1.1), which satisfies the regularity of the data needed for our main results.

    Assumption (A1)(see[27,28]): Assume that the boundary of Ω is smooth so that the unique solution (v,q) of the steady Stokes problem

    Δv+q=f,v=0inΩ,v|Ω=0,

    for prescribed fL2(Ω)3 satisfies

    v2+q1cf0,

    and Maxwell's equations

    curlcurlB=g,B=0inΩ,n×curlB=0,BnonΩ,

    for the prescribed gL2(Ω)3 admits a unique solution BW0 which satisfies

    B2cg0.

    Assumption (A2): The initial data u0,B0,f satisfy

    Au00+B02+sup0tTf0+ft0C. (2.3)

    Assumption (A3): We assume that the MHD problem admits a unique local strong solution (u,p,B) on (0,T) such that

    sup0tTAut0+Bt2+p1+ut0+Bt0+T0(ut21+Bt21+pt21+utt20+Btt20)dtC. (2.4)

    Let 0=t0<t1<<tN=T be a uniform partition of the time interval [0,T] with tn=nτ, and N being a positive integer. Set un=(,tn), For any sequence of functions {fn}Nn=0, we define

    Dτfn=fnfn1τ.

    At the initial time step, we start with U0=˜U0=u0,B0=˜B0=b0 and an arbitrary P0MH1(Ω). Then, we can give

    P0=f0u0u0+νΔu0μB0×curlB0.

    Then, we give the algorithm as follows

    Algorithm 2.1 (Time-discrete modified characteristics projection finite element method)

    Step 1. Solve Bn+1, for instance

    Bn+1ˆBnτ+curlcurlBn+1(Bn)Un=gn+1, (2.5)
    Bn+1n=0,n×curlBn+1=0, on Ω, (2.6)

    where

    ˆln={ln(ˆx),   ˆx=xUnτΩ,0,   othrewise.

    Step 2. Find ˜Un+1, such that

    ˜Un+1ˆUnτνΔ˜Un+1+Pn+μBn×curlBn+1=fn+1, (2.7)
    ˜Un+1=0, on Ω. (2.8)

    Step 3. Calculate (Un+1,Pn+1), for example

    Un+1˜Un+1τ+(Pn+1Pn)=0, (2.9)
    Un+1=0, (2.10)
    Un+1=0 on Ω,. (2.11)

    The corresponding weak form is

    Step 1. Solve Bn+1, for instance

    (Bn+1ˆBnτ,ψ)+(curlBn+1,curlψ)((Bn)Un,ψ)=(gn+1,ψ),   ψW. (2.12)

    Step 2. Find ˜Un+1, such that

    (˜Un+1ˆUnτ,v)+ν(˜Un+1,v)+(Pn,v)+μ(Bnv,Bn+1)μ(vBn,Bn)=(fn+1,v),   vX, (2.13)

    Step 3. Calculate (Un+1,Pn+1), for example

    (Un+1˜Un+1τ,v)+((Pn+1Pn),v)=0,   vX, (2.14)
    (Un+1,ϕ)=0,   ϕM. (2.15)

    Remark 2.1 As we all know (Bn×curlBn+1,v)=(Bnv,Bn+1)(vBn,Bn+1). In order to improve our algorithm, we change it as (Bnv,Bn+1)(vBn,Bn).

    We denote Th be a regular and quasi-uniform partition of the domain Ω into the triangles for d=2 or tetrahedra for d=3 with diameters by a real positive parameter h(h0). The finite element pair (Xh,Mh,Wh) is constructed based on Th.

    Let Wh0n=Xh×Wh. There exits a constant β0>0 (only dependent on Ω) such that

    sup0(v,ψ)Wh0nd(v,q)v0β0q0,  qMh. (2.16)

    There exits a mapping rhL(H2(Ω)2V,Xh) satisfying

    ((vrhv),q)=0,(vrhv)0Chv2,  vH2(Ω)2V,  qMh,

    and a L2-projection operator ρh:MMh satisfying

    qρhq0Chq1,  qH1(Ω)M,

    and a mapping RhL(H2(Ω)2Vn,Wh) satisfying

    (×RhΦ,×Ψ)+(RhΦ,Ψ)=(×Φ,×Ψ)+(Φ,Ψ)=(×Φ,×Ψ),  ΨWh,ΦRhΦ0+hΦRhΦ1Ch2Φ2,  H2(Ω)Vh.

    Here, we define the discrete Stokes operator Ah=Phh and h (see [15] and the references therein) defined by

    (huh,vh)=(uh,vh),uh,vhVh.

    Meanwhile, we define the discrete operator A1hBh=R1h(h××Bh+hBh)Wh (see [15]) as follows

    (A1hBh,Ψ)=(A121hBh,A121hBh)=(×Bh,×Ψ)+(Bh,Ψ),Bh,ΨWh.

    We define the Stokes projection (Rh(u,p),Qh(u,P)):(X,M)(Xh,Mh) by

    ν(Rh(u,p)u,vh)(Qh(u,p)p,vh)=0, (2.17)
    ((Rh(u,p)u),ϕh)=0. (2.18)

    By classical FEM theory ([25,29,30]), we have the following results.

    Lemma 2.2 Assume that uH10(Ω)dHr+1(Ω)d and pL20(Ω)Hr(Ω). Then,

    Rh(u,p)u0+h((Rh(u,p)u)0+Qh(u,p)p0)Chr+1(ur+1+pr), (2.19)

    and

    Rh(u,p)LC(u2+p1). (2.20)

    Lemma 2.3 If (u,p)W2,k(Ω)d×W1,k(Ω) for k>d,

    Rh(u,p)LC(uW1,+pL). (2.21)

    Algorithm 2.2 (The fully discrete modified characteristics projection finite element method)

    Step 1. Solve Bn+1h, for instance

    (Bn+1hˆBnhτ,ψh)+(curlBn+1h,curlψh)((Bnh)unh,ψh)=(gn+1,ψh),   ψhWh. (2.22)

    where

    ˆlnh={lnh(ˆx),   ˆx=xunhτΩ,0,   othrewise.

    Step 2. Find ˜Un+1, such that

    (˜un+1hˆunhτ,vh)+ν(˜un+1h,vh)+(pnh,vh)+μ(Bnhvh,Bn+1h)μ(vhBnh,Bnh)=(fn+1,vh),   vhXh. (2.23)

    Step 3. Calculate (un+1h,pn+1h), for example

    (un+1h˜un+1hτ,vh)+((pn+1hpnh),vh)=0,   vhXh, (2.24)
    (un+1h,ϕh)=0,   ϕhMh. (2.25)

    Here, we make use of the following notation:

    en=unUn,˜e=un˜Un,n=0,1,...,N,εn=bnBn,ˆεn=bnˆBn,n=0,1,...,N,ξn=pnPn,n=0,1,...,N.

    Lemma 3.1 (see[31]). Assume that g1,g2,ρ are three functions defined in Ω and ρ|Ω=0. If

    τ(g1W1,+g2W1,)12,

    then

    ρ(xg1(x)τ)ρ(xg2(x)τ)LqCτρW1,q2g1g2Lq1,ρ(xg1(x)τ)ρ(xg2(x)τ)1Cτρ0g1g2W1,,

    where 1/q1+1/q2=1/q,1<q<.

    The following theorem gives insight on the error estimate between the time-discrete solution and the solution of the time-dependent MHD system (1.1).

    Theorem 3.1 Suppose that assumption A2–A3 are satisfied, there exists a positive C>0 such that

    max0nm(em+120+μεm+120)+mn=0(en+1en20+μεn+1εn20),+τmn=0(ν˜en+120+μcurlεn+120)Cτ2,max0nm(νem+121+μcurlεm+120)+τmn=1(νen+1en21+μcurlεn+1curlεn20)+τmn=1(Dτen+120+μDτεn+120)Cτ2,τmn=0(en+122+˜en+122+εn+122)Cτ2,τmn=0(DτUn+122+Dτ˜Un+122+DτPn+121+DτBn+122+Un+12W2,d+Bn+12W2,d)+max0nm(Un+12+˜Un+12+Pn+11+Bn+12)C.

    Proof. Firstly, we prove the following inequality

    em2+τ3/4UmW2,d1, (3.1)
    εm2+τ3/4BmW2,d1, (3.2)

    by mathematical induction for m=0,1,...,N.

    Since U0=u0,B0=b0 the above inequality hold for m=0.

    We assume that (3.1) and (3.2) hold for mn for some integer n0. By Sobolev embedding theory, we get

    UmLumL+Cem2C, (3.3)
    BmLbmL+Cεm2C, (3.4)

    and

    τUmW1,1/4, (3.5)
    τBmW1,1/4, (3.6)

    when ττ1 for some positive constant τ1.

    To prove (3.1) and (3.2) for m=n+1, we rewrite (1.1) by

    Dτun+1νΔun+1+pn+1=fn+1unˉunτ+Rn+1tr1μbn+1×curlbn+1, (3.7)
    un+1=0, (3.8)
    Dτbn+1+curlcurlbn+1=gn+1bnˉbnτ+Rn+1tr2+bn+1un+1. (3.9)

    where un+1=U(tn+1),bn+1=B(tn+1), and

    ˉln={ln(ˉx),ˉx=xunτΩ,0,otherwise.

    and

    Rn+1tr1=un+1ˉunτun+1t(un+1)un+1,Rn+1tr2=bn+1ˉbnτbn+1t(un+1)bn+1,

    define the truncation error. We can refer to ([31]), there holds that

    τNm=1Rmtr120Cτ2,τNm=1Rmtr220Cτ2. (3.10)

    The corresponding weak form is

    (Dτun+1,v)+ν(un+1,v)(pn+1,v)=(fn+1,v)(unˉunτ,v)+(Rn+1tr1,v)μ(bn+1×curlbn+1,v), (3.11)
    (un+1,ϕ)=0, (3.12)
    (Dτbn+1,ψ)+(curlbn+1,curlψ)=(gn+1,ψ)(bnˉbnτ,ψ)+(Rn+1tr2,ψ)+(bn+1(un+1un),ψ)+(bn+1un,ψ). (3.13)

    Combining (2.13) and (2.14), we obtain

    (Un+1ˆUnτ,v)+ν(˜Un+1,v)(Pn+1,v)+μ(Bnv,Bn+1)μ(vBn,Bn)=(fn+1,v). (3.14)

    Then, we rewrite (3.14) and (2.12) as

    (DτUn+1,v)+ν(˜Un+1,v)(Pn+1,v)=(fn+1,v)(UnˆUnτ,v)μ(Bnv,Bn+1)+μ(vBn,Bn), (3.15)

    and

    (DτBn+1,ψ)+(curlBn+1,curlψ)=(gn+1,ψ)+(BnUn,ψ)(BnˆBnτ,ψ). (3.16)

    Subtracting (3.15) and (3.16) from (3.11) and (3.13), respectively, leads to

    (Dτen+1,v)+ν(˜en+1,v)(ξn+1,v)=(unˉun(UnˆUn)τ,v)+(Rn+1tr1,v)μ((bn+1bn)vv(bn+1bn),bn+1)+μ(vbn,bn+1bn)+μ(vεn,bn)+μ(vBn,εn)μ(εnv,bn+1)μ(Bnv,εn+1), (3.17)

    and

    (Dτεn+1,ψ)+(curlεn+1,curlψ)=(bnˉbn(BnˆBn)τ,ψ)+(Rn+1tr2,ψ)+(bn+1(un+1un)+(bn+1bn)un+εnun+Bnen,ψ). (3.18)

    Testing (2.9) by τen+1, since en+1=0, we arrive at

    (en+1,˜en+1)=(en+1,en+1). (3.19)

    Testing (2.9) by τen, we get

    (en,˜en+1)=(en,en+1). (3.20)

    Subtracting (3.20) from (3.19), we can obtain

    (en+1en,˜en+1)=(en+1en,en+1). (3.21)

    Let v=2τ˜en+1 in (3.17), we obtain

    en+120en20+en+1en20+2ντ˜en+1202τ(ξn+1,˜en+1)=2((en(ˉunˆUn),˜en+1)+2τ(Rn+1tr1,˜en+1)2μτ((bn+1bn)˜en+1˜en+1(bn+1bn),bn)+2μτ(˜en+1bn,bn+1bn)+2μτ(˜en+1εn,bn)+2μτ(˜en+1Bn,εn)2μτ(εn˜en+1,bn+1)2μτ(Bn˜en+1,εn+1). (3.22)

    Let ψ=2μτεn+1 in (3.18), we get

    μεn+120μεn20+μεn+1εn20+2μτcurlεn+120=2μ(εn(ˉbnˆBn),εn+1)+2μτ(Rn+1tr2,εn+1)+2μτ(bn+1(un+1un)+(bn+1bn)un+εnun+Bnen,εn+1). (3.23)

    Taking sum of (3.22) and (3.23) yields

    en+120en20+μεn+120μεn20+en+1en20+μεn+1εn20+2ντ˜en+120+2μτcurlεn+1202τ(ξn+1,˜en+1)=2(enˆen,˜en+1)2(ˆunˉun,˜en+1)+2τ(Rn+1tr1,˜en+1)2μτ((bn+1bn)˜en+1,bn)+2μτ(˜en+1(bn+1bn),bn)+2μτ(˜en+1bn,bn+1bn)+2μτ(˜en+1εn,bn)+2μτ(˜en+1Bn,εn)2μτ(εn˜en+1,bn+1)2μτ(Bn˜en+1,εn+1)2μ(εnˆεn,εn+1)2μ(ˆbnˉbn,εn+1)+2μτ(Rn+1tr2,εn+1)+2μτ(bn+1(un+1un),εn+1)+2μτ((bn+1bn)un,εn+1)+2μτ(εnunεn+1)+2μτ(Bnen,εn+1). (3.24)

    From (2.9), we have

    ˜en+1=en+1+τ(ξn+1ξn)τ(pn+1pn).

    Then, we can obtain

    2τ(ξn+1,˜en+1)=2τ(ξn+1,en+1)+2τ2(ξn+1,(ξn+1ξn))4τ2(ξn+1,(pn+1pn))=τ2(ξn+120ξn20+ξn+1ξn20)2τ2(ξn+1,(pn+1pn))τ2(ξn+120ξn20+(ξn+1ξn)20)Cτ2ξn+10(pn+1pn)0=τ2(ξn+120ξn20+(ξn+1ξn)20)τ(Cτξn+10(pn+1pn)0)τ2(ξn+120ξn20+(ξn+1ξn)20)τ(Cτ2ξn+120+14(pn+1pn)20)=τ2(ξn+120ξn20+(ξn+1ξn)20)Cτ3ξn+120+14(pn+1pn)20).

    On the other hand, using Lemma 3.1, we deduce that

    2|(enˆen,˜en+1)|2enˆen1˜en+10Cτen0UnW1,˜en+10ντ12˜en+120+Cτen20,2|(ˆunˉun,˜en+1)|CˆunˉunL6/5˜en+1L6CτunL3en0˜en+10ντ12˜en+120+Cτen20,2τ|(Rn+1tr1,˜en+1)|Rn+1tr10˜en+10ντ12˜en+120+CτRn+1tr120,2μτ|((bn+1bn)˜en+1,bn+1)|Cτbn+1bn0˜en+10bn+12ντ12˜en+120+Cτ3bn+1t20bn+122,2μτ|(˜en+1(bn+1bn),bn+1)|Cτ˜en+1L6bn+1L3bn+1bn0ντ12˜en+120+Cτ3bn+1t20bn+122,2μτ|(˜en+1bn,bn+1bn)|Cτ˜en+1L6bn+1L3bn+1bn0ντ12˜en+120+Cτ3bn+1t20bn+122,2μτ|(˜en+1εn,bn)|Cτ˜en+10bn2εn0ντ12˜en+120+Cτεn20bn22,2μτ|(˜en+1Bn,εn)|Cτ˜en+10BnLεn0ντ12˜en+120+Cτεn20Bn2L,2μτ|(εn˜en+1,bn+1)|Cτεn0˜en+10bn+1Lντ12˜en+120+Cτεn20bn+122,2μτ|(Bn˜en+1,εn+1)|CτBnL˜en+10εn+10ντ12˜en+120+Cτεn20,2μτ|(εnˆεn,εn+1)|Cτεn0BnW1,εn+10μτ8curlεn+120+Cτεn20,2μτ|(ˆbnˉbn,εn+1)|CτˆbnˉbnL6/5εn+1L6CτbnL3εn0εn+10μτ8curlεn+120+Cτεn20,2μτ|(Rn+1tr2,εn+1)|CτRn+1tr20εn+10μτ8curlεn+120+CτRn+1tr220,2μτ|(bn+1(un+1un),εn+1)|Cτbn+12un+1un0curlεn+10μτ8curlεn+120+Cτun+1un20,2μτ|((bn+1bn)un,εn+1)|Cτbn+1bn0unLεn+10μτ8curlεn+120+Cτ3bn+1t20un2L,2μτ|(εnun,εn+1)|Cτεn0unL3curlεn+10μτ8curlεn+120+Cτεn20un2L3,2μτ|(Bnen,εn+1)|CτBnLen0curlεn+10μτ8curlεn+120+Cτen20.

    Substituting these above inequality into (3.24), we obtain

    en+120en20+μεn+120μεn20+τ2ξn+120τ2ξn20+en+1en20+μεn+1εn20+τ2(ξn+1ξn)20+ντ˜en+120+μτcurlεn+120Cτ(en20+εn20+εn+120)+Cτ(Rn+1tr120+Rn+1tr220)+Cτ3(ξn+120+ξn20)+Cτ3. (3.25)

    Taking sum of the (3.25) for n from 0 to mN and using discrete Gronwall's inequality Lemma 2.1, we get

    max0nm(em+120+μεm+120+τ2ξm+120)+mn=0(en+1en20+μεn+1εn20)+τmn=0(ν˜en+120+μcurlεn+120)Cτ2. (3.26)

    Owing to (3.21), we have

    ((en+1en),˜en+1)=((en+1en),en+1). (3.27)

    To acquire the H1 estimates, we take v=2τDτen+1 in (3.17) to get

    ν(en+121en21+en+1en21)+2τDτen+120=2((en(ˉunˆUn),Dτen+1)+2τ(Rn+1tr1,Dτen+1)2μτ((bn+1bn)Dτen+1Dτen+1(bn+1bn),bn+1)+2μτ(Dτen+1bn,bn+1bn)+2μτ(Dτen+1εn,bn)+2μτ(Dτen+1Bn,εn)2μτ(εnDτen+1,bn+1)2μτ(BnDτen+1,εn+1). (3.28)

    Then, we take ψ=2μτDτεn+1 in (3.18) to get

    μ(curlεn+120curlεn20+curlεn+1curlεn20)+2μτDτεn+120=2μ(εn(ˉbnˆBn),Dτεn+1)+2μτ(Rn+1tr2,Dτεn+1)+2μτ(bn+1(un+1un)+(bn+1bn)un+εnun+Bnen,Dτεn+1). (3.29)

    Combining (3.28) and (3.29), we obtain

    ν(en+121en21+en+1en21)+μ(curlεn+120curlεn20+curlεn+1curlεn20)+2τDτen+120+2ντDτεn+120=2(enˆen,Dτen+1)2(ˆunˉun,Dτen+1)+2τ(Rn+1tr1,Dτen+1)2μτ((bn+1bn)Dτen+1,bn+1)+2μτ(Dτen+1(bn+1bn),bn+1)+2μτ(Dτen+1bn,bn+1bn)+2μτ(Dτen+1εn,bn)+2μτ(Dτen+1Bn,εn)2μτ(εnDτen+1,bn+1)2μτ(BnDτen+1,εn+1)2μ(εnˆεn,εn+1)2μ(ˆbnˉbn,Dτεn+1)+2μτ(Rn+1tr2,Dτεn+1)+2μτ(bn+1(un+1un),Dτεn+1)+2μτ((bn+1bn)un,Dτεn+1)+2μτ(εnun,Dτεn+1)+2μτ(Bnen,Dτεn+1). (3.30)

    Similarly, by Lemma 3.1, we have

    2|(enˆen,Dτen+1)|2enW1,2UnLDτen+10τ16Dτen+120+Cτen21,2|(ˆunˉun,Dτen+1)|CunW1,4enL4Dτen+10CunW1,4en1Dτen+10τ16Dτen+120+Cτen21,2τ|(Rn+1tr1,Dτen+1)|Rn+1tr10Dτen+10τ16Dτen+120+CτRn+1tr120,2μτ|((bn+1bn)Dτen+1,bn+1)|Cτ(bn+1bn)0Dτen+10bn+12τ16Dτen+120+Cτ3bn+1t20bn+122,2μτ|(Dτen+1(bn+1bn),bn+1)|CτDτen+10(bn+1bn)0bn+12τ16Dτen+120+Cτ3bn+1t20bn+122,2μτ|(Dτen+1bn,bn+1bn)|CτDτen+10bnLbn+1bn0τ16Dτen+120+Cτ3bn+1t20bn2L,2μτ|(Dτen+1εn,bn)|CτDτen+10εn0bnLτ16Dτen+120+Cτcurlεn20bn2L,2μτ|(Dτen+1Bn,εn)|CτDτen+10BnL3εnL6τ16Dτen+120+Cτεn20Bn2L3,τ16Dτen+120+Cτcurlεn20Bn2L3,2μτ|(εnDτen+1,bn+1)|Cτεn0Dτen+10bn+12τ16Dτen+120+Cτcurlεn20bn+122,2μτ|(BnDτen+1,εn+1)|CτBnLεn+10Dτen+10τ16Dτen+120+Cτcurlεn+120Bn2L,2μτ|(εnˆεn,Dτεn+1)|CτεnW1,2BnLDτεn+10μτ8Dτεn+120+Cτcurlεn20,2μτ|(ˆbnˉbn,Dτεn+1)|CτbnL4εnL4Dτεn+10μτ8Dτεn+120+Cτcurlεn20,2μτ|(Rn+1tr2,Dτεn+1)|CτRn+1tr20Dτεn+10μτ8Dτεn+120+CτRn+1tr220,2μτ|(bn+1(un+1un),Dτεn+1)|Cτbn+12(un+1un)0Dτεn+10μτ8Dτεn+120+Cτ(un+1un)20,2μτ|((bn+1bn)un,Dτεn+1)|Cτbn+1bn0unLDτεn+10μτ8Dτεn+120+Cτ3bn+1t20un2L,2μτ|(εnun,Dτεn+1)|Cτεn0unLDτεn+10μτ8Dτεn+120+Cτcurlεn20un2L,2μτ|(Bnen,Dτεn+1)|CτBnLen0Dτεn+10μτ8Dτεn+120+Cτen20Bn2L.

    Substituting these above inequality into (3.30), we obtain

    ν(en+121en21+en+1en21)+μ(curlεn+120curlεn20+curlεn+1curlεn20)+τDτen+120+μτDτεn+120Cτ(en21+curlεn+120+curlεn20)+Cτ(Rn+1tr120+Rn+1tr220)+Cτ3. (3.31)

    Taking sum of the (3.31) for n from 0 to mN and using discrete Gronwall's inequality Lemma 2.1, we arrive at

    max0nm(νem+121+μcurlεm+120)+τmn=1(νen+1en21+μcurlεn+1curlεn20)+τmn=1(Dτen+120+μDτεn+120)Cτ2. (3.32)

    Furthermore, the standard result for (3.17) and (3.18) with p=2, respectively, leads to

    ˜en+12CDτen+10+Cτenˆen0+CτˆUnˉUn0+CRn+1tr10+Cbn+1bn0bn+1L+Cbn+1bn0bn+1L+CbnLbn+1bn0+Cεn0bnL+CBnW1,εn0+Cεn0bn+1L+CBnLcurlεn+10+ξn+11CDτen+10+CRn+1tr10+ξn+11+Cτ, (3.33)
    εn+12CDτεn+10+Cτεnˆεn0+Cτˆbnˉbn0+CRn+1tr20+Cbn+1Lun+1un0+Cbn+1bn0unL+Cεn0unL+CBnLen0CDτen+10+CRn+1tr0+Cτ. (3.34)

    Thanks to (3.19), we can obtain

    (Δen+1,Δen+1)=(Δ˜en+1,Δen+1),en+12˜en+12.

    Then, we have

    τmn=0(en+122+˜en+122+εn+122)Cτ2. (3.35)

    From (3.35), we can arrive at

    max0nmUn+12max0nm(un+12+en+12)C, (3.36)
    max0nm˜Un+12max0nm(un+12+˜en+12)C, (3.37)
    max0nmPn+11max0nm(pn+11+ξn+11)C, (3.38)
    max0nmBn+12max0nm(bn+12+εn+12)C, (3.39)
    τmn=0DτUn+1222τmn=0(Dτun+122+Dτen+122)C, (3.40)
    τmn=0Dτ˜Un+1222τmn=0(Dτun+122+Dτ˜en+122)C, (3.41)
    τmn=0DτPn+1212τmn=0(Dτpn+121+Dτξn+121)C, (3.42)
    τmn=0DτBn+1222τmn=0(Dτbn+122+Dτεn+122)C. (3.43)

    From (2.7) and (2.5), we have

    DτUn+1νΔ˜Un+1+Pn+1=fn+1UnˆUnτμBn×curlBn+1, (3.44)

    and

    DτBn+1+curlcurlBn+1=gn+1+(Bn)UnBn+1ˆBnτ. (3.45)

    By (2.9), we have

    ΔUn+1=×טUn+1. (3.46)

    Considering the identity 2˜Un+1=˜Un+1×טUn+1 and (3.46), we can obtain

    Δ˜Un+1=˜Un+1ΔUn+1. (3.47)

    Now, the standard result for the Stokes system (3.17) and (3.18) with p=d>2, respectively, leads to

    Un+1W2,d+Pn+1˜Un+1W1,dCDτUn+1Ld+CτˆUnUnLd+Cfn+1Ld+CBn×curlBn+1LdC(DτUn+1Ld+UnLdUnL+fn+1Ld+BnLdcurlBn+1Ld), (3.48)
    Bn+1W2,dCDτBn+1Ld+Cgn+1Ld+CτˆBnBnLd+CBnUnLdC(DτBn+1Ld+gn+1Ld+BnLdBnL+BnLdUnLd). (3.49)

    By (3.48) and (3.49), we get

    τmn=0(Un+12W2,d+Bn+12W2,d)C. (3.50)

    Thus, we can obtain

    en+12+τ3/4Un+1W2,d1, (3.51)
    εn+12+τ3/4Bn+1W2,d1. (3.52)

    The proof is complete.

    For the sake of simplicity, we denote Rnh=Rh(Un,Pn),Qnh=Qh(Un,Pn),R0h=R0hBn,n=1,2,...,N, and enh=unhRnh,˜enh=˜unhRnh,εnh=BnhRn0h,n=1,2,...,N, where R0h:L2(Ω)3Wh is the L2-orthogonal projection, where

    R0hww0+h(R0hww)0Chr+1wr+1, (3.53)
    R0hwLCw2, (3.54)
    R0hwLCwW1,. (3.55)

    Theorem 3.2 Suppose that assumption A2–A3 are satisfied, there exists a positive C>0 such that

    um+1h20+μBm+1h20+mn=0(un+1hunh20+μBn+1hBnh20)+τmn=0(ν˜un+1h20+μcurlBn+1h20)C,um+1h21+μcurlBm+1h20+mn=0(un+1hunh21+μcurlBn+1hcurlBnh20)+τmn=0(νAun+1h20+μcurlBn+1h20)C,em+1h20+μεm+1h20+mn=0(en+1henh20+μεn+1hεnh20)+τmn=0(ν˜en+1h20+μcurlεn+1h20)Ch4,un+1h2L+μBn+1h2L+τmn=0(un+1h2W1,+μBn+1h2W1,)C.

    Proof. We prove following estimates

    emh20+μεmh20+τnm=0(νemh20+μcurlεmh20)Ch4, (3.56)

    by mathematical induction for m=0,1,...,N.

    When m=0,u0h=u0,B0h=B0. It is obvious (3.56) holds at the initial time step. We assume that (3.56) holds for 0mn for some integer n0. By (2.20), (2.21), (3.54), (3.55), Theorem 3.1 and inverse inequality, we infer

    τumhW1,(emhW1,+RmhW1,)C(hd2emh0+UmW1,+PmL)14, (3.57)
    τBmhW1,(εmhW1,+Rm0hW1,)C(hd2εmh0+BmW1,)14, (3.58)

    and

    τumhL(emhL+RmhL)C(hd2emh0+Um2+Pm1)C, (3.59)
    τBmhL(εmhL+Rm0hL)C(hd2εmh0+Bm2)C. (3.60)

    Combining (2.23) and (2.24), we obtain

    (un+1hˆunhτ,vh)+ν(˜un+1h,vh)(pn+1h,vh)+μ(Bnhvh,Bn+1h)μ(vhBnh,Bnh)=(fn+1,vh). (3.61)

    When m=n+1, letting vh=2τ˜un+1h in (3.61), we can obtain

    2(un+1hunh+unhˆunh,˜un+1h)+2ντ(˜un+1h,˜un+1h)2τ(pn+1h,˜un+1h)+2μτ(Bnh˜un+1h,Bn+1h)2μτ(˜un+1hBnh,Bnh)=2τ(fn+1,˜un+1h). (3.62)

    Letting vh=τun+1h in (2.24), since un+1h=0, it follows that

    (un+1h,˜un+1h)=(un+1h,un+1h). (3.63)

    Taking vh=τunh in (2.24), we get

    (unh,˜un+1h)=(unh,un+1h). (3.64)

    Subtracting (3.64) from (3.63), we can obtain

    (un+1hunh,˜un+1h)=(un+1hunh,un+1h). (3.65)

    Using 2(ab,a)=a20b20+ab20, leads to

    un+1h20unh20+un+1hunh20+2ντ˜un+1h202τ(pn+1h,˜un+1h)=2τ(fn+1,˜un+1h)+2(ˆunhunh,˜un+1h)2μτ(Bnh˜un+1h,Bn+1h). (3.66)

    Taking vh=pn+1h in (2.24), we deduce

    2τ(pn+1h,˜un+1)=2τ2pn+1h202τ2pnh20+2τ2pn+1hpnh20. (3.67)

    When m=n+1, letting ψh=2μτBn+1h in (2.22), we can obtain

    2μ(Bn+1hBnh+BnhˆBnh,Bn+1h)+2μτ(curlBn+1h,curlBn+1h)2μτ(Bnhunh,Bn+1h)=2μτ(gn+1,Bn+1h). (3.68)

    Using 2(ab,a)=a20b20+ab20, we have

    μBn+1h20μBnh20+μBn+1hBnh20+2μτcurlBn+1h20=2μτ(gn+1,Bn+1h)+2μτ(Bnhunh,Bn+1h)+2μ(ˆBnhBnh,Bn+1h). (3.69)

    Taking sum of (3.66) and (3.69) yields

    un+1h20unh20+μBn+1h20μBnh20+2τ2pn+1h202τ2pnh20+un+1hunh20+μBn+1hBnh20+2τ2pn+1hpnh20+2ντ˜un+1h20+2μτcurlBn+1h20=2τ(fn+1,˜un+1h)+2μτ(gn+1,Bn+1h)+2(ˆunhunh,˜un+1h)2μτ(Bn˜un+1h,Bn+1h)+2μ(ˆBnhBnh,Bn+1h)+2μτ(Bnhunh,Bn+1h). (3.70)

    Then, we can obtain

    2τ|(fn+1,˜un+1h)|Cτfn+10˜un+1h0ντ4˜un+1h20+Cτfn+120,2μτ|(gn+1,Bn+1h)|Cτgn+10Bn+1h0μτ4curlBn+1h20+Cτgn+120,2|(ˆunhunh,˜un+1h)|Cτˆunhunh6/5˜un+1hL6CτunhL3unh0˜un+1h0ντ4˜un+1h20+Cτunh20,2μτ|(Bn˜un+1h,Bn+1h)|CτBnL˜un+1h0Bn+1h0ντ4˜un+1h20+CτBn+1h20,2μ|(ˆBnhBnh,Bn+1h)|CτˆBnhBnh1Bn+1h1CτBnh0BnhW1,curlBn+1h0μτ4curlBn+1h20+CτBnh20Bnh2W1,,2μτ|(Bnunh,Bn+1h)|CτBnLunh0curlBn+1h0μτ4curlBn+1h20+Cτunh20.

    Substituting these above estimates into (3.70), we obtain

    un+1h20unh20+μBn+1h20μBnh20+τ2pn+1h20τ2pnh20+un+1hunh20+μBn+1hBnh20+2τ2pn+1hpnh20+ντ˜un+1h20+μτcurlBn+1h20Cτfn+120+Cτgn+120+Cτunh20+CτBnh20. (3.71)

    Taking sum of the (3.71) for n from 0 to mN and using discrete Gronwall's inequality Lemma 2.1, we get

    um+1h20+μBm+1h20+τ2pm+1h20+mn=0(un+1hunh20+μBn+1hBnh20)+τmn=0(ν˜un+1h20+μcurlBn+1h20)C.

    Letting vh=2τAun+1h in (3.61), we obtain

    2(un+1hunh+unhˆunh,Aun+1h)+2ντ(A˜un+1h,Aun+1h)+2μτ(BnhAun+1h,Bn+1h)2μτ(Aun+1hBnh,Bnh)=2τ(fn+1,Aun+1h). (3.72)

    From (3.63), we arrive at

    (A˜un+1h,Aun+1h)=(Aun+1h,Aun+1h),(A˜un+1h,Aun+1h)=Aun+1h20.

    Using 2(ab,a)=a20b20+ab20, leads to

    un+1h21unh21+un+1hunh21+2ντAun+1h20=2τ(fn+1,Aun+1h)+2(ˆunhunh,Aun+1h)2μτ(BnhAun+1h,Bn+1h). (3.73)

    Letting ψh=2μτcurlcurlBn+1h in (2.22), we can obtain

    μcurlBn+1h20μcurlBnh20+μcurlBn+1hcurlBnh20+2μτcurlcurlBn+1h20=2μτ(gn+1,curlcurlBn+1h)+2μτ(Bnhunh,curlcurlBn+1h)+2μ(ˆBnhBnh,curlcurlBn+1h). (3.74)

    Taking sum of (3.73) and (3.74) yields

    un+1h21unh21+μcurlBn+1h20μcurlBnh20+un+1hunh21+μcurlBn+1hcurlBnh20+2ντAun+1h20+2μτcurlcurlBn+1h20=2τ(fn+1,Aun+1h)+2(ˆunhunh,Aun+1h)+2τ(gn+1,curlcurlBn+1h)2μτ(BnhAun+1h,Bn+1h)+2μτ(Bnhunh,curlcurlBn+1h)+2μ(ˆBnhBnh,curlcurlBn+1h). (3.75)

    Then, we get

    2τ|(fn+1,Aun+1h)|Cτfn+10Aun+1h0ντ6Aun+1h20+Cτfn+120,2μτ|(gn+1,curlcurlBn+1h)|Cτgn+10curlcurlBn+1h0μτ4curlcurlBn+1h20+Cτgn+120,2|(ˆunhunh,Aun+1h)|CτunhW1,4unhL4Aun+1h0ντ6Aun+1h20+Cτunh21,2μτ|(BnhAun+1h,Bn+1h)|CτBnhW1,Aun+1h0Bn+1h0ντ6Aun+1h20+CτcurlBn+1h20,2μτ|(Bnhunh,curlcurlBn+1h)|CτBnhLunh0curlcurlBn+1h0μτ4curlcurlBn+1h20+Cτunh20,2μ|(ˆBnhBnh,curlcurlBn+1h)|CτBnhW1,4BnhL4curlcurlBn+1h0μτ4curlcurlBn+1h20+CτBnh2W1,4Bnh2L4μτ4curlcurlBn+1h20+CτcurlBnh20.

    Substituting these above estimates into (3.75), we obtain

    un+1h21unh21+μcurlBn+1h20μcurlBnh20+un+1hunh21+μcurlBn+1hcurlBnh20+ντAun+1h20+μτcurlcurlBn+1h20Cτfn+120+Cτgn+120+Cτunh21+Cτ(curlBn+1h20+curlBnh20). (3.76)

    Taking sum of the (3.76) for n from 0 to mN and using discrete Gronwall's inequality Lemma 2.1, we get

    um+1h21+μcurlBm+1h20+mn=0(un+1hunh21+μcurlBn+1hcurlBnh20)+τmn=0(νAun+1h20+μcurlcurlBn+1h20)C.

    Then, we rewrite (3.61) and (2.22) as

    (Dτun+1h,vh)+ν(˜un+1h,vh)(Pn+1h,vh)=(fn+1,vh)(unhˆunhτ,vh)μ(Bnhvh,Bn+1h)+μ(vhBnh,Bnh), (3.77)

    and

    (DτBn+1h,ψh)+(curlBn+1h,curlψh)=(gn+1,ψh)+(Bnhunh,ψh)(BnhˆBnhτ,ψh). (3.78)

    Subtracting (3.15) and (3.16) from (3.77) and (3.78), respectively, leads to

    (Dτen+1h,vh)+ν(˜en+1h,vh)(pn+1hQn+1h,vh)=(Dτ(Un+1Rn+1h),vh)+(ˆunhunhτ,vh)+(UnˆUnτ,vh)μ(εnhvh,Bn+1h)μ((Rn0hBn)vh,Bn+1h)μ(Bnvh,εn+1h)μ(Bnvh,Rn+10hBn+1)+μ(vhεnh,Bnh)+μ(vhBn,εnh)μ(vhBn,Rn0hBn)+μ(vh(Rn0hBn),Bnh), (3.79)

    and

    (Dτεn+1h,ψh)+(curlεn+1h,curlψnh)=(Dτ(Bn+1Rn+10h),ψh)+(BnhˆBnhτ,ψh)+(ˆBnBnτ,ψh)+(εnhunh,ψh)+((Rn0hBn)unh,ψh)+(Bn(RnhUn),ψh)+(Bnenh,ψh). (3.80)

    Taking vh=2τen+1h in (2.24), we can obtain

    (en+1h,˜en+1h)=(en+1h,en+1h),(Dτen+1h,˜en+1h)=(Dτen+1h,en+1h),(en+1h,˜en+1h)=(en+1h,en+1h)=en+1h20.

    Let θn=UnRnh,ηn=BnRn0h. By taking vh=2τen+1h in (3.79), we deduce

    en+1h20enh20+en+1henh20+2ντen+1h20=2τ(DτUn+1Rh(DτUn+1,DτPn+1),en+1h)+2(ˆenhenh,en+1h)+2(θnˆθn,en+1h)2μτ(εnhen+1h,Bn+1h)2μτ(ηnen+1h,Bn+1h)2μτ(Bnen+1h,εn+1h)2μτ(Bnen+1h,ηn+1)+2μτ(en+1hεnh,Bnh)+2μτ(en+1hBn,εnh)+2μτ(en+1hBn,ηn)+2μτ(en+1hηn,Bnh). (3.81)

    By taking ψh=2μτεn+1h in (3.80), we have

    μεn+1h20μεnh20+μεn+1hεnh20+2μτcurlεn+1h20=2τ(DτBn+1R0hDτBn+1),εn+1h)+2μ(εnhˆεnh,εn+1h)+2μ(ηnˆηn,εn+1h)+2μτ(εnhunh,εn+1h)2μτ(ηnunh,εn+1h)+2μτ(Bn(RnhUn),εn+1h)+2μτ(Bnenh,εn+1h). (3.82)

    Combining (3.81) and (3.82), we obtain

    en+1h20enh20+μεn+1h20μεnh20+en+1henh20+Sεn+1hεnh20+2ντen+1h20+2μτcurlεn+1h20=2τ(DτUn+1Rh(DτUn+1,DτPn+1),en+1h)+2(ˆenhenh,en+1h)+2(θnˆθn,en+1h)2μτ(εnhen+1h,Bn+1h)2μτ(ηnen+1h,Bn+1h)2μτ(Bnen+1h,Bn+1h)2μτ(Bnen+1h,ηn+1)+2μτ(en+1hεnh,Bnh)+2μτ(en+1hBn,εnh)+2μτ(en+1hBn,ηn)+2μτ(en+1hηn,Bnh)+2τ(DτBn+1R0hDτBn+1),εn+1h)+2μ(εnhˆεnh,εn+1h)+2μ(ηnˆηn,εn+1h)+2μτ(εnhunh,εn+1h)2μτ(ηnunh,εn+1h)+2μτ(Bn(RnhUn),εn+1h)2μτ(Bnenh,Bn+1h). (3.83)

    Due to (2.19) and Theorem 3.1, we can get θn0Ch2(Un2+Pn1)Ch2, ηn0Ch2Bn2. By Lemma 3.1, there holds that

    2τ|(DτUn+1Rh(DτUn+1,DτPn+1),en+1h)|Cτh2en+1h0(DτUn+12+DτPn+11)ντ20en+1h20+Cτh4(DτUn+122+DτPn+121),2|(ˆenhenh,en+1h)|Cenhˆenh1en+1h0Cτenh0unhW1,en+1h0ντ20en+1h20+Cτenh20,2|(θnˆθn,en+1h)|Cθnˆθn1en+1h0Cτθn0unhW1,en+1h0ντ20en+1h20+Cτθn20,2μτ|(εnhen+1h,Bn+1h)|Cτεnh0en+1h0Bn+1hLντ20en+1h20+Cτεnh20,2μτ|(ηnen+1h,Bn+1h)|Cτηn0en+1h0Bn+1hLντ20en+1h20+Cτηn20,2μτ|(Bnen+1h,εn+1h)|CτBnLen+1h0εn+1h0ντ20en+1h20+Cτεn+1h20,2μτ|(Bnen+1h,ηn+1)|CτBn2en+1h0ηn+10ντ20en+1h20+Cτηn+120,2μτ|(en+1hεnh,Bnh)|Cτen+1h0εnh0BnhLντ20en+1h20+Cτεnh20,2μτ|(en+1hBn,εn+1h)|Cτen+1h0Bn2εnh0ντ20en+1h20+Cτεnh20,2μτ|(en+1hBn,ηn)|Cτen+1h0Bn2ηn0ντ20en+1h20+Cτηn20,2μτ|(en+1hηn,Bnh)|Cτen+1h0ηn0BnhLντ20en+1h20+Cτηn20,2τ|(DτBn+1R0hDτBn+1,εn+1h)|Cτh2εn+1h0DτBn+12ηn0μτ16curlεn+1h20+Cτh4DτBn+122,2μ|(εnhˆεnh,εn+1h)|Cεnhˆεnh0εn+1h0Cτcurlεnh0BnhLεn+1h0μτ16curlεn+1h20+Cτεn+1h20,2μ|(ηnˆηn,εn+1h)|Cηnˆηn1εn+1h0Cτηn0BnhW1,curlεn+1h0μτ16curlεn+1h20+Cτηn20,2μτ|(εnhunh,εn+1h)|Cτεnh0unhL3εn+1hL6μτ16curlεn+1h20+Cτεn+1h20,2μτ|(ηnunh,εn+1h)|Cτηn0unhL3εn+1hL6μτ16curlεn+1h20+Cτηn20,2μτ|(Bn(RnhUn),εn+1h)|CτBn2θn0εn+1h0μτ16curlεn+1h20+Cτθn20,2μτ|(Bnenh,εn+1h)|CτBnLenh0curlεn+1h0μτ16curlεn+1h20+Cτenh20.

    Substituting these above estimates into (3.83), we obtain

    en+1h20enh20+μεn+1h20μεnh20+en+1henh20+μεn+1hεnh20+ντen+1h20+μτcurlεn+1h20Cτ(enh20+εnh20+εn+1h20)+Cτh4. (3.84)

    Taking the sum of the (3.76) for n from 0 to mN and using the discrete Gronwall's inequality Lemma 2.1, we get

    em+1h20+μεm+1h20+mn=0(en+1henh20+μεn+1hεnh20)+τmn=0(νen+1h20+μcurlεn+1h20)Ch4.

    Then, we can deduce

    max0nmun+1hLmax0nm(Rn+1hL+en+1hL)Cmax0nmUn+12+Cmax0nmPn+11+Ch12max0nmen+1h0C,max0nmBn+1hLmax0nm(Rn+10hL+εn+1hL)Cmax0nmBn+12+Ch12max0nmεn+1h0C,τmn=0un+1h2W1,2τmn=0(Rn+1h2W1,+en+1h2W1,)Cτmn=0(Un+12W1,+Pn+12L)+Cτh2mn=0en+1h20C,τmn=0Bn+1h2W1,2τmn=0(Rn+10h2W1,+εn+1h2W1,)Cτmn=0Bn+12W1,+Cτh2mn=0εn+1h20C.

    Thus, all the results in Theorem 3.2 have been proved.

    In order to show the effect of our method, we present some numerical results. Here, we consider the

    u1=(y+y4)cos(t),u2=(x+x2)cos(t),p=(2.0x1.0)(2.0y1.0)cos(t),B1=(sin(y)+y)cos(t),B2=(sin(x)+x2)cos(t).

    The boundary conditions and the forcing terms are given by the exact solution. The finite element spaces are chosen as P1b-P1-P1b finite element spaces. Here, we choose τ=h2 and h=1/n, n=8,16,24,32,40,48. Different Reynolds number Re and magnetic Reynolds number Rm are chosen to show the effect of our method, the numerical results were shown in Tables 16. Here, we use the software package FreeFEM++ [32] for our program.

    Table 1.  The numerical results for Re=1.0 and Rm=1.0 for different h at T=1.0.
    1/h u1hu0 (u1hu1)0 p1hp0 B1hB0 (B1hB)0 E1hE0 |ΩBdx| |Ωudx|
    8 0.00395939 0.104518 0.0633311 0.00146071 0.0443105 0.0402426 4.95209e-17 1.99024e-14
    16 0.00109704 0.0527177 0.0212408 0.000384435 0.0221793 0.0208612 1.41995e-16 4.15508e-15
    24 0.000473611 0.0347495 0.0118957 0.000175071 0.0148256 0.0141051 5.03032e-17 5.95751e-15
    32 0.000256132 0.0258999 0.010131 9.82405e-05 0.0111161 0.010656 3.35182e-16 7.38832e-15
    40 0.000160786 0.0206654 0.00831346 6.2778e-05 0.00889124 0.00856254 7.97451e-16 5.55468e-15
    48 0.000110796 0.0171977 0.00648101 4.35568e-05 0.00740848 0.00715659 1.00015e-16 4.15077e-15

     | Show Table
    DownLoad: CSV
    Table 2.  Convergence order for Re=1.0 and Rm=1.0 for different h at T=1.0.
    1/h uL2 uH1 PL2 BL2 BH1
    16 1.85166 0.987389 1.57608 1.92586 0.998435
    24 2.07166 1.02792 1.42982 1.93995 0.99343
    32 2.13671 1.0217 0.5582 2.00837 1.00097
    40 2.08665 1.01181 0.88607 2.00685 1.00084
    48 2.04246 1.00748 1.36571 2.00491 1.00066

     | Show Table
    DownLoad: CSV
    Table 3.  The numerical results for Re=100.0 and Rm=100.0 for different h at T=1.0.
    1/h u1hu0 (u1hu1)0 p1hp0 B1hB0 (B1hB)0 E1hE0 |ΩBdx| |Ωudx|
    8 0.0172667 0.279161 0.0354359 0.0127351 0.19731 0.00779509 3.41253e-17 3.17954e-14
    16 0.00233046 0.0697115 0.01409 0.00240034 0.0479792 0.00159673 9.63754e-17 1.3337e-14
    24 0.000831767 0.0398145 0.00892872 0.000977778 0.0269431 0.000711847 8.03834e-18 8.42217e-15
    32 0.000422379 0.0280313 0.00649219 0.000527044 0.0184095 0.000385869 2.36579e-16 5.31439e-15
    40 0.000256947 0.0217553 0.00511173 0.000330314 0.013926 0.000239563 7.44033e-16 2.85026e-15
    48 0.000173343 0.0178297 0.00421705 0.000226765 0.0112143 0.000162916 7.14376e-17 2.41418e-15

     | Show Table
    DownLoad: CSV
    Table 4.  Convergence order for Re=100.0 and Rm=100.0 for different h at T=1.0.
    1/h uL2 uH1 PL2 BL2 BH1
    16 2.88931 2.00163 1.33054 2.4075 2.03998
    24 2.54095 1.38147 1.12512 2.21495 1.42315
    32 2.35555 1.21978 1.10773 2.1482 1.32391
    40 2.22742 1.13589 1.07134 2.09391 1.2508
    48 2.1588 1.09144 1.05529 2.063 1.1878

     | Show Table
    DownLoad: CSV
    Table 5.  The numerical results for Re=1000.0 and Rm=1000.0 for different h at T=1.0.
    1/h u1hu0 (u1hu1)0 p1hp0 B1hB0 (B1hB)0 E1hE0 |ΩBdx| |Ωudx|
    8 0.0397337 1.68458 0.0330041 0.029124 1.17999 0.0213862 1.41814e-16 1.99053e-14
    16 0.00470743 0.368592 0.0137702 0.00403407 0.219747 0.00228304 7.44847e-17 1.26213e-14
    24 0.00158913 0.177215 0.00901776 0.00143967 0.106852 0.000843484 8.59434e-17 8.328e-15
    32 0.000750714 0.102493 0.00644056 0.000756826 0.0713168 0.000456685 2.75943e-16 5.37049e-15
    40 0.000430867 0.0675245 0.00509083 0.000460115 0.0510193 0.000286991 8.76007e-16 2.73806e-15
    48 0.000276193 0.0481754 0.00421193 0.000306103 0.038122 0.000195792 1.25266e-16 2.4751e-15

     | Show Table
    DownLoad: CSV
    Table 6.  Convergence order for Re=1000.0 and Rm=1000.0 for different h at T=1.0.
    1/h uL2 uH1 PL2 BL2 BH1
    16 3.07735 2.19229 1.26109 2.8519 2.42487
    24 2.6783 1.80614 1.04402 2.54119 1.77829
    32 2.60675 1.90339 1.16997 2.23523 1.40541
    40 2.48819 1.8701 1.05392 2.23021 1.50095
    48 2.43909 1.85191 1.03949 2.23536 1.59834

     | Show Table
    DownLoad: CSV

    Tables 1 and 2 give the numerical results for Re=1.0 and Rm=1.0. In order to show the effect of our method for high Reynolds number, we give the numerical results for Re=100.0, 1000.0 and Rm=100.0, 1000.0. Tables 3 and 4 give the numerical results for Re=100.0 and Rm=100.0. Tables 5 and 6 give the numerical results for Re=1000.0 and Rm=1000.0. It shows that our method is effect for high Reynolds numbers. It shows that the errors are goes small as the space step goes small and the convergence orders are optimal. We can see that |ΩBdx| and |Ωudx| are small, which means that our method can conserve the Gauss's law very well.

    In this paper, we have given a modified characteristics projection finite element method for the unsteady incompressible magnetohydrodynamics(MHD) equations. In this method, the modified characteristics finite element method and the projection method were combined for solving the incompressible MHD equations. Both the stability and the optimal error estimates in L2 and H1 norms for the modified characteristics projection finite element method have been given. In order to demonstrate the effectiveness of our method, some numerical results were given at the end of the manuscript.

    The authors would like to thank the anonymous referees for their valuable suggestions and comments, which helped to improve the quality of the paper. This work is supported in part by National Natural Science Foundation of China (No. 11971152), China Postdoctoral Science Foundation (No. 2018M630907) and the Key scientific research projects Henan Colleges and Universities (No. 19B110007).

    The authors declare there is no conflict of interest in this paper.



    Conflict of interest



    The authors have no conflict of interest to declare.

    Authors' contribution



    The contributions of all authors have been invaluable to the completion of this paper. The corresponding author, served as both mentor and guide, provided critical support by thoroughly evaluating the work throughout the writing process and offering valuable insights that significantly aided the co-authors, ultimately leading to the successful publication of this article.

    [1] Simon DK, Tanner CM, Brundin P (2020) Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med 36: 1-12. https://doi.org/10.1016/j.cger.2019.08.002
    [2] Fang JY (2022) Parkinson disease. Primer on the Autonomic Nervous System, Fourth Edition.Academic Press 549-552. https://doi.org/10.1016/B978-0-323-85492-4.00061-2
    [3] Lewis PA (2012) James Parkinson: The man behind the Shaking Palsy. J Parkinsons Dis 2: 181-187. https://doi.org/10.3233/JPD-2012-012108
    [4] Francis S, Medical E (1964) James Parkinson. Med Sci 15: 95.
    [5] Saini N, Singh N, Kaur N, et al. (2024) Motor and non-motor symptoms, drugs, and their mode of action in Parkinson's disease (PD): a review. Med Chem Res 33: 580-599. https://doi.org/10.1007/s00044-024-03203-5
    [6] van Wamelen DJ, Martinez-Martin P, Weintraub D, et al. (2021) The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. Acta Neurol Scand 143: 3-12. https://doi.org/10.1111/ane.13336
    [7] Rodriguez-Sanchez F, Rodriguez-Blazquez C, Bielza C, et al. (2021) Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Sci Rep 11: 23645. https://doi.org/10.1038/s41598-021-03118-w
    [8] World Health OrganizationParkinson disease (2023). Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
    [9] Ou Z, Pan J, Tang S, et al. (2021) Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Front Public Heal 9: 776847. https://doi.org/10.3389/fpubh.2021.776847
    [10] Arun M, Thomas PT, Kamble NL, et al. (2023) Disability Certification for Parkinson's Disease in India: Challenges and the Way Forward. Indian J Community Med 48: 639-640. https://doi.org/10.4103/ijcm.ijcm_972_22
    [11] Ball N, Teo WP, Chandra S, et al. (2019) Parkinson's disease and the environment. Front Neurol 10: 421551. https://doi.org/10.3389/fneur.2019.00218
    [12] Clarimón J (2020) Genetic-environmental factors finally assessed together in Parkinson's disease. J Neurol Neurosurg Psychiatry 91: 1030. https://doi.org/10.1136/jnnp-2020-324472
    [13] Periñán MT, Brolin K, Bandres-Ciga S, et al. (2022) Effect Modification between Genes and Environment and Parkinson's Disease Risk. Ann Neurol 92: 715-724. https://doi.org/10.1002/ana.26467
    [14] Li W, Fu YH, Halliday GM, et al. (2021) PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease. Front Cell Dev Biol 9: 612476. https://doi.org/10.3389/fcell.2021.612476
    [15] Parkinson's Foundation. New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson's Disease by 2030. Available from: https://www.parkinson.org/about-us/news/parkinsons-prevalence-project
    [16] Fields CR, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci 12. https://doi.org/10.3389/fnmol.2019.00299
    [17] Saramowicz K, Siwecka N, Galita G, et al. (2024) Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson's Disease. Int J Mol Sci 25. https://doi.org/10.3390/ijms25010360
    [18] Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508: 1-12. https://doi.org/10.1016/j.abb.2010.12.017
    [19] Harsing LG (2008) Dopamine and the Dopaminergic Systems of the Brain. Handbook of Neurochemistry and Molecular Neurobiology. Boston, MA: Springer. https://doi.org/10.1007/978-0-387-30382-6_7
    [20] Klein MO, Battagello DS, Cardoso AR, et al. (2019) Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol 39: 31-59. https://doi.org/10.1007/s10571-018-0632-3
    [21] Brücke T, Brücke C (2022) Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders. J Neural Transm 129: 581-594. https://doi.org/10.1007/s00702-021-02452-7
    [22] Lin MK, Farrer MJ (2014) Genetics and genomics of Parkinson's disease. Genome Med 6: 1-16. https://doi.org/10.1186/gm566
    [23] Sayyaed A, Saraswat N, Vyawahare N, et al. (2023) A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson's disease with insights into screening models. Bull Natl Res Cent 47. https://doi.org/10.1186/s42269-023-01047-4
    [24] Day JO, Mullin S (2021) The genetics of parkinson's disease and implications for clinical practice. Genes (Basel) 12: 1006. https://doi.org/10.3390/genes12071006
    [25] Funayama M, Nishioka K, Li Y, et al. (2023) Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet 68: 125-130. https://doi.org/10.1038/s10038-022-01058-5
    [26] Trinh J, Zeldenrust FMJ, Huang J, et al. (2018) Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33: 1857-1870. https://doi.org/10.1002/mds.27527
    [27] Lehrer S, Rheinstein PH (2022) α-synuclein enfolds tyrosine hydroxylase and dopamine ß-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. J Proteins Proteomics 13: 109-115. https://doi.org/10.1007/s42485-022-00088-z
    [28] Calabresi P, Di Lazzaro G, Marino G, et al. (2023) Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease. Brain 146: 3587-3597. https://doi.org/10.1093/brain/awad150
    [29] Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. (2021) Alpha-Synuclein Aggregation in Parkinson's Disease. Front Med 8: 736978. https://doi.org/10.3389/fmed.2021.736978
    [30] Wang YN, Shi XY, Yin YP, et al. (2024) Association Between Neuroinflammation and Parkinson's Disease: A Comprehensive Mendelian Randomization Study. Mol Neurobiol . https://doi.org/10.1007/s12035-024-04197-2
    [31] Arena G, Sharma K, Agyeah G, et al. (2022) Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop. Curr Neurol Neurosci Rep 22: 427-440. https://doi.org/10.1007/s11910-022-01207-5
    [32] Lee Y, Lee S, Chang SC, et al. (2019) Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention. Arch Pharmacal Res 42: 416-425. https://doi.org/10.1007/s12272-019-01133-0
    [33] Perez RG (2020) Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease. Front Neurosci 14: 528856. https://doi.org/10.3389/fnins.2020.00116
    [34] Tonda-Turo C, Origlia N, Mattu C, et al. (2018) Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers. Curr Med Chem 25: 5755-5771. https://doi.org/10.2174/0929867325666180221125759
    [35] Pardo-Moreno T, García-Morales V, Suleiman-Martos S, et al. (2023) Current Treatments and New, Tentative Therapies for Parkinson's Disease. Pharm 15: 770. https://doi.org/10.3390/pharmaceutics15030770
    [36] Stoker TB, Torsney KM, Barker RA (2018) Emerging treatment approaches for Parkinson's disease. Front Neurosci 12: 419092. https://doi.org/10.3389/fnins.2018.00693
    [37] Kola S, Subramanian I (2023) Updates in Parkinson's Disease Integrative Therapies: an Evidence-Based Review. Curr Neurol Neurosci Rep 23: 717-726. https://doi.org/10.1007/s11910-023-01312-z
    [38] Serva SN, Bernstein J, Thompson JA, et al. (2022) An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation. Front Surg 9: 863921. https://doi.org/10.3389/fsurg.2022.863921
    [39] Lee ESY, Chen H, King J, et al. (2008) The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res 33: 401-411. https://doi.org/10.1007/s11064-007-9442-6
    [40] Li W, Zheng M, Wu S, et al. (2017) Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 36: 1-12. https://doi.org/10.1186/s13046-017-0530-4
    [41] Hollingworth SA, McGuire TM, Pache D, et al. (2015) Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. Drugs - Real World Outcomes 2: 199-203. https://doi.org/10.1007/s40801-015-0028-3
    [42] Jost WH (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. J Neural Transm 129: 723-736. https://doi.org/10.1007/s00702-022-02465-w
    [43] Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59: 1233-1250. https://doi.org/10.2165/00003495-200059060-00004
    [44] Laatikainen O, Sneck S, Turpeinen M (2022) Medication-related adverse events in health care—what have we learned? A narrative overview of the current knowledge. Eur J Clin Pharmacol 78: 159. https://doi.org/10.1007/s00228-021-03213-x
    [45] Chen JF, Cunha RA (2020) The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. Purinergic Signal 16: 167-174. https://doi.org/10.1007/s11302-020-09694-2
    [46] Vanegas-Arroyave N, Caroff SN, Citrome L, et al. (2024) An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders. CNS Drugs 38: 239-254. https://doi.org/10.1007/s40263-024-01078-z
    [47] Church DS, Church MK (2011) Pharmacology of Antihistamines. World Allergy Organ J 4: S22-S27. https://doi.org/10.1186/1939-4551-4-S3-S22
    [48] Ntetsika T, Papathoma PE, Markaki I (2021) Novel targeted therapies for Parkinson's disease. Mol Med 27: 1-20. https://doi.org/10.1186/s10020-021-00279-2
    [49] Bougea A (2024) Some Novel Therapies in Parkinson's Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomed 12: 549. https://doi.org/10.3390/biomedicines12030549
    [50] Okun MS, Hickey PT, Machado AG, et al. (2022) Temporally optimized patterned stimulation (TOPS®) as a therapy to personalize deep brain stimulation treatment of Parkinson's disease. Front Hum Neurosci 16. https://doi.org/10.3389/fnhum.2022.929509
    [51] Lewis S, Radcliffe E, Ojemann S, et al. (2024) Pilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease. Neuromodulation 27: 509-519. https://doi.org/10.1016/j.neurom.2023.01.006
    [52] Rossi M, Cerquetti D, Mandolesi J, et al. (2016) Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease. Park Dis Curr Futur Ther Clin Trials : 175-186.
    [53] Hamel W, Köppen JA, Müller D, et al. (2019) The pioneering and unknown stereotactic approach of roeder and orthner from Göttingen. Part II: Long-Term Outcome and Postmortem Analysis of Bilateral Pallidotomy in the Pre-Levodopa Era. Stereotact Funct Neurosurg 96: 353-363. https://doi.org/10.1159/000495412
    [54] Sharma VD, Patel M, Miocinovic S (2020) Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches. Neurotherapeutics 17: 1525-1538. https://doi.org/10.1007/s13311-020-00939-x
    [55] Bhansali AP, Gwinn RP (2020) Ablation: Radiofrequency, Laser, and HIFU. Stereotactic and Functional Neurosurgery. Cham: Springer 223-233. https://doi.org/10.1007/978-3-030-34906-6_16
    [56] Intemann PM, Masterman D, Subramanian I, et al. (2001) Staged bilateral pallidotomy for treatment of Parkinson disease. J Neurosurg 94: 437-444. https://doi.org/10.3171/jns.2001.94.3.0437
    [57] Franzini A, Moosa S, Servello D, et al. (2019) Ablative brain surgery: an overview. Int J Hyperth 36: 64-80. https://doi.org/10.1080/02656736.2019.1616833
    [58] Kostiuk K (2023) Stereotactic Staged Asymmetric Bilateral Radiofrequency Lesioning for Parkinson's Disease. Stereotact Funct Neurosurg 101: 359-368. https://doi.org/10.1159/000534084
    [59] Aradi SD, Hauser RA (2020) Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurother 17: 1339-1365. https://doi.org/10.1007/s13311-020-00889-4
    [60] Chaudhuri KR, Kovács N, Pontieri FE, et al. (2023) Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results. J Parkinsons Dis 13. https://doi.org/10.3233/JPD-225105
    [61] Fasano A, García-Ramos R, Gurevich T, et al. (2023) Levodopa–carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS. J Neurol 270: 2765-2775. https://doi.org/10.1007/s00415-023-11615-3
    [62] Baek H, Lockwood D, Mason EJ, et al. (2022) Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders. Front Neurol 13: 880814. https://doi.org/10.3389/fneur.2022.880814
    [63] Meng Y, Hynynen K, Lipsman N (2020) Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol 17: 7-22. https://doi.org/10.1038/s41582-020-00418-z
    [64] Pandey SK, Singh RK (2022) Recent developments in nucleic acid-based therapies for Parkinson's disease: Current status, clinical potential, and future strategies. Front Pharmacol 13: 986668. https://doi.org/10.3389/fphar.2022.986668
    [65] Dumbhare O, Gaurkar SS (2023) A Review of Genetic and Gene Therapy for Parkinson's Disease. Cureus 15: e34657. https://doi.org/10.7759/cureus.34657
    [66] Jamebozorgi K, Taghizadeh E, Rostami D, et al. (2019) Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Mol Neurobiol 56: 4799-4811. https://doi.org/10.1007/s12035-018-1419-8
    [67] Galetta S, Ganesh A, Lewis A, et al. (2022) Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes from the PD-1101 Trial. Neurology 99: 258. https://doi.org/10.1212/WNL.0000000000201001
    [68] Paccosi E, Proietti-De-Santis L (2023) Parkinson's Disease: From Genetics and Epigenetics to Treatment, a miRNA-Based Strategy. Int J Mol Sci 24: 9547. https://doi.org/10.3390/ijms24119547
    [69] Panda S, Chatterjee O, Chatterjee S (2023) Nucleic Acid-Based Strategies to Treat Neurodegenerative Diseases. Nucleic Acid Biol its Appl Hum Dis 105–133. https://doi.org/10.1007/978-981-19-8520-1_4
    [70] Burbulla LF, Zheng J, Song P, et al. (2021) Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. JCI Insight 6. https://doi.org/10.1172/jci.insight.148649
    [71] Pinjala P, Tryphena KP, Prasad R, et al. (2023) CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease. Biomater Res 27. https://doi.org/10.1186/s40824-023-00381-y
    [72] Zafar F, Valappil RA, Kim S, et al. (2018) Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. npj Parkinson's Disease 4: 18. https://doi.org/10.1038/s41531-018-0054-4
    [73] Ho Yoon H, Ye S, Lim S, et al. (2020) CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson's disease. bioRxiv . https://doi.org/10.1101/2020.08.27.269522
    [74] Flores-Fernandez JM, Pesch V, Sriraman A, et al. (2023) Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders. bioRxiv . https://doi.org/10.1101/2023.06.30.547254
    [75] Duwa R, Jeong JH, Yook S (2021) Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson's disease. J Pharm Investig 51: 465-481. https://doi.org/10.1007/s40005-021-00521-3
    [76] Antonini A, Bravi D, Sandre M, et al. (2020) Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. Expert Opin Investig Drugs 29: 685-695. https://doi.org/10.1080/13543784.2020.1771693
    [77] Jamal F (2020) Immunotherapies Targeting α-Synuclein in Parkinson Disease. Fed Pract 37: 375-379. https://doi.org/10.12788/fp.0026
    [78] Nimmo JT, Smith H, Wang CY, et al. (2022) Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol 143: 55-73. https://doi.org/10.1007/s00401-021-02381-5
    [79] Folke J, Ferreira N, Brudek T, et al. (2022) Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomol 12: 168. https://doi.org/10.3390/biom12020168
    [80] TAK-341 | ALZFORUM. Available from: https://www.alzforum.org/therapeutics/tak-341
    [81] Al-Tuwairqi SM, Badrah AA (2023) Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy. AIMS Math 8: 1800-1832. https://doi.org/10.3934/math.2023093
    [82] Knecht L, Folke J, Dodel R, et al. (2022) Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective. Neurotherapeutics 19: 1489-1502. https://doi.org/10.1007/s13311-022-01288-7
    [83] Prasinezumab Failure in Parkinson's Phase 2 Trial Detailed | Further Study Underway of Antibody Targeting Alpha-synuclein | Parkinson's News Today. Available from: https://parkinsonsnewstoday.com/news/prasinezumab-failure-parkinsons-phase-2-trial-detailed/
    [84] Stefanis L (2012) α-Synuclein in Parkinson's disease. CSH Perspect Med 2: a009399. https://doi.org/10.1101/cshperspect.a009399
    [85] Pagano G, Taylor KI, Anzures-Cabrera J, et al. (2022) Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med 387: 421-432. https://doi.org/10.1056/NEJMoa2202867
    [86] Wang F, Sun Z, Peng D, et al. (2023) Cell-therapy for Parkinson's disease: a systematic review and meta-analysis. J Transl Med 21: 1-22. https://doi.org/10.1186/s12967-023-04484-x
    [87] Liu Z, Cheung HH (2020) Stem Cell-Based Therapies for Parkinson Disease. Int J Mol Sci 21: 8060. https://doi.org/10.3390/ijms21218060
    [88] Morizane A (2023) Cell therapy for Parkinson's disease with induced pluripotent stem cells. Inflamm Regen 43: 1-5. https://doi.org/10.1186/s41232-023-00269-3
    [89] Nasrolahi A, Shabani Z, Sadigh-Eteghad S, et al. (2024) Stem Cell Therapy for the Treatment of Parkinson's Disease: What PromiseDoes it Hold?. Curr Stem Cell Res Ther 19: 185-199. https://doi.org/10.2174/1574888X18666230222144116
    [90] Gautam A, Bali S (2023) Role of Ai in the Diagnosis and Management of Parkinsonism. Int J Med Pharm Res 4: 393-397.
    [91] Ouyang A (2022) Artificial intelligence model can detect Parkinson's from breathing patterns. MIT News . Available from: https://news.mit.edu/2022/artificial-intelligence-can-detect-parkinsons-from-breathing-patterns-0822.
    [92] Saravanan S, Ramkumar K, Adalarasu K, et al. (2022) A Systematic Review of Artificial Intelligence (AI) Based Approaches for the Diagnosis of Parkinson's Disease. Arch Comput Methods Eng 29: 3639-3653. https://doi.org/10.1007/s11831-022-09710-1
    [93] Dixit S, Bohre K, Singh Y, et al. (2023) A Comprehensive Review on AI-Enabled Models for Parkinson's Disease Diagnosis. Electron 12. https://doi.org/10.3390/electronics12040783
    [94] McFarthing K, Buff S, Rafaloff G, et al. (2023) Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. J Parkinsons Dis 13: 427-439. https://doi.org/10.3233/JPD-239901
    [95] Enogieru AB, Haylett W, Hiss DC, et al. (2018) Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. Oxid Med Cell Longev : 6241017. https://doi.org/10.1155/2018/6241017
    [96] Hauser RA, Giladi N, Poewe W, et al. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther 39: 1881-1894. https://doi.org/10.1007/s12325-022-02097-2
    [97] Bette S, Shpiner DS, Singer C, et al. (2018) Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag 14: 1737. https://doi.org/10.2147/TCRM.S139545
    [98] Mertsalmi TH, Pekkonen E, Scheperjans F (2020) Antibiotic exposure and risk of Parkinson's disease in Finland: A nationwide case-control study. Mov Disord 35: 431-442. https://doi.org/10.1002/mds.27924
    [99] Nakamori M, Junn E, Mochizuki H, et al. (2019) Nucleic Acid-Based Therapeutics for Parkinson's Disease. Neurotherapeutics 16: 287-298. https://doi.org/10.1007/s13311-019-00714-7
    [100] Brandacher G, Perathoner A, Ladurner R, et al. (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 12: 1144-1151. https://doi.org/10.1158/1078-0432.CCR-05-1966
    [101] WO2012075473A1 - Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters - Google Patents. Available from: https://patents.google.com/patent/WO2012075473A1/en17
    [102] Kolwicz SC, Olson DP, Marney LC, et al. (2019) ACC inhibitors and uses thereof. Circ Res 111: 728-738. https://doi.org/10.1161/CIRCRESAHA.112.268128
    [103] Michael E. Bozik, Thomas Petzinger, Jr., Valentin Gribkoff, Inventors; Knopp Neurosciences, Inc. Assignee. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same. Google Patents US8524695B2. 2013 Sep. 3. Available from: https://patents.google.com/patent/US8524695B2/en?oq=US8524695B2
    [104] JP6556146B2 - Heterocyclic compounds - Google Patents. Available from: https://patents.google.com/patent/JP6556146B2/en?oq=JP6556146B2
    [105] ES2723876T3 - New pyrazole derivatives - Google Patents. Available from: https://patents.google.com/patent/ES2723876T3/en?oq=ES2723876T3
    [106] CN109125261B - Edaravone dosage form - Google Patents. Available from: https://patents.google.com/patent/CN109125261B/en?oq=CN109125261B
    [107] Administration TD, Insuline OD, Soir LE Tepzz_59 4¥8b_t (11) (2014)1: 1-31.
    [108] JP2018118914A - Pharmaceutical for ameliorating neurodegenerative diseases - Google Patents. Available from: https://patents.google.com/patent/JP2018118914A/en?oq=JP2018118914A
    [109] CA2806444C - Prodrugs of methyl hydrogen fumarate - Google Patents. Available from: https://patents.google.com/patent/CA2806444C/en?oq=16.CA2806444CMethyl+Hydrogen+Fumarate+(MHF)+Immunomodulation+inhibits+inflammatory+mediators+and+interaction+with+the+TNF+signaling+pathways.23%2F02%2F201619%2F08%2F2029
    [110] CN102755310B - A kind of composition medicine preparation containing levodopa - Google Patents. Available from: https://patents.google.com/patent/CN102755310B/en?oq=CN102755310B
    [111] JP7443606B2 - Novel catecholamine prodrugs for use in the treatment of Parkinson's disease - Google Patents. Available from: https://patents.google.com/patent/JP7443606B2/en?oq=18.JP7443606B2(4aR%2C+10aR)-1-n-propyl-1%2C2%2C3%2C4%2C4a%2C5%2C10%2C10a-octahydro-benzo[g]quinoline-6%2C7-diolDopamine+agonist%2C+provides+dopaminergic+innervation+to+the+striatum+and+other+brain+regions%2C+ultimately+affecting+the+basal+ganglia+circuitry05%2F03%2F202423%2F11%2F2038
    [112] JP6251259B2 - Novel 5-aminotetrahydroquinoline-2-carboxylic acid and use thereof - Google Patents. Available from: https://patents.google.com/patent/JP6251259B2/en?oq=19.JP6251259B25-amino-5%2C6%2C7%2C8-tetrahydroquinoline-2-carboxylic+acidSoluble+guanylate+cyclase+(sGC)+activator%2C+stimulating+the+biosynthesis+of+cGMP+from+GTP20%2F12%2F201716%2F07%2F2033
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1470) PDF downloads(31) Cited by(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog